Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
13 Results Found
AHA Details Legislative Priorities for Congressional Leaders
Hospitals and health systems are experiencing significant financial pressures that challenge their ability to provide 24/7 care for the patients and communities they serve. As Congress begins to focus on its end-of-the-year work, America’s hospitals and health systems respectfully request that you consider the following priorities.
AHA Letter to FTC and DOJ Re: Anticompetitive Activity by Drug Companies with Respect to 340B “Rebate Models”
AHA letter to the Federal Trade Commission and Department of Justice regarding anticompetitive activity by drug companies with respect to 340B “rebate models.”
AHA Comments to HRSA on Proposed 340B Rebate Model Pilot Program
AHA comments on the Health Resources and Services Administration’s notice of the 340B Rebate Model Pilot Program.
AHA, Health Associations Comment on HRSA Notice of a 340B Rebate Model Pilot Program
AHA, health associations initial comment on the Health Resources and Services Administration’s (HRSA) notice of a 340B Rebate Model Pilot Program.
AHA Urges HHS to Reject the Effort by Several Large Drug Companies to Undermine the 340B Drug Pricing Program
AHA urges Secretary U.S. Department of Health and Human Services to reject the effort by several large drug companies to undermine the 340B Drug Pricing Program by imposing a “rebate model,”
AHA Letter to CMS on Medicare Transaction Facilitator and Drug Negotiation Program
AHA shares feedback in response to the Centers for Medicare & Medicaid Services’ information collection request (ICR) regarding the Medicare Transaction Facilitator (MTF) and the Medicare drug negotiation program.
AHA Urges HRSA to Take Immediate Enforcement Action to Block J&J’s Illegal Imposition of 340B Rebate Model
AHA letter regarding the Health Resources and Services Administration’s response to Johnson & Johnson’s (J&J) most recent attempt to undermine the 340B Drug Pricing Program.
AHA Comments on 340B Drug Pricing Program, IRF Payments, Physician Fee Schedule and Telehealth
AHA comments on MedPAC topics to be considered in the new cycle: the 340B Drug Pricing Program, inpatient rehabilitation facility (IRF) payments, the physician fee schedule (PFS) and telehealth.
AHA Comments Opposing the 340B ACCESS Act (H.R. 8574)
The American Hospital Association (AHA) expresses their opposition to H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net (340B ACCESS) Act.
AHA Submits Comments on CMS Guidance For Medicare Drug Price Negotiation Program
AHA shares feedback on the Centers for Medicare & Medicaid Services’ draft guidance on the Medicare drug price negotiation program.